science wire



Results 1201 - 1250 of 1511.

Pharmacology - Health - 21.06.2013
FDA grants Breakthrough Therapy designation to Novartis’ serelaxin (RLX030) for acute heart failure
Recognition by the US Food and Drug Administration (FDA) that RLX030 has the potential to address a serious unmet medical need If approved, RLX030 has the potential to be the first treatment breakthrough for Acute Heart Failure patients in 20 years[1,2] RLX030 is the second Breakthrough Therapy designation by the FDA for Novartis investigational treatments, following LDK378 Basel, June 21 , 2013 - Novartis announced today that the US Food and Dr

Pharmacology - Health - 16.06.2013
Novartis drug Jakavi improved overall survival of myelofibrosis patients and impacted an underlying mechanism of disease
Jakavi reduced risk of death by 52% and sustained reductions in spleen size in new three-year COMFORT-II study data Analysis from a separate trial suggested that long-term treatment with Jakavi may stabilize or improve bone marrow fibrosis, a key marker of worsening disease Basel, June 16, 2013 - Novartis today announced results from a Phase III three-year follow-up study that showed Jakavi (ruxolitinib) demonstrated improved overall survival and sustained reductions in spleen size compared to conventional therapy.

Pharmacology - Life Sciences - 10.06.2013
Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple sclerosis
Gilenya resulted in almost 50% more patients being free of MS disease activity after the switch from standard interferon treatment Annualized relapse rate reduced by >50% after 1 year for patients who switched from standard interferon treatment to Gilenya Reduced rate of brain volume loss sustained for up to 4.5 years in patients with active disease, despite prior treatment, who switched from interferon to Gilenya Basel, June 10 , 2013

Pharmacology - Health - 05.06.2013
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
Gilenya improved the key measures: brain volume loss, MRI lesion activity, relapse rates and disability progression Switching to Gilenya from interferon increased the proportion of patients disease free after one year of treatment Gilenya resulted in sustained reduction of annualized relapse rate and the rate of brain volume loss in patients switched from interferon treatment Basel, June 5 , 2013 - New data will be presented at the 23 rd meeting

Pharmacology - Health - 03.06.2013
Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer
Investigational compound LDK378 is a selective inhibitor of ALK , a target found in metastatic non-small cell lung cancer (NSCLC) Data show 60% overall response rate in 78 patients with ALK+ NSCLC taking LDK378 at 750 mg; will serve as basis for first filing in early 2014 FDA designated LDK378 as Breakthrough Therapy in March and a robust clinical development plan is underway Basel, June 3 , 2013 - Novartis today announced data on its investigat

Health - Pharmacology - 02.06.2013
Novartis pivotal Phase III trial shows Afinitor significantly delays tumor growth in HER2 positive advanced breast cancer
A 22% reduction in the risk of disease progression was seen with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients First Phase III study sho

Health - Pharmacology - 31.05.2013
Lucentis receives positive opinion for patients with myopic choroidal neovascularization showing vision gains with only two injections
Lucentis recommended for approval in EU to treat patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Lucentis superior to current standard of care and i

Health - Pharmacology - 29.05.2013
Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
Latest Phase III research on Afinitor in HER2 positive advanced breast cancer Jakavi TM overall survival advantage evaluated in three-year study in patients with myelofibrosis, a rare and life-threat

Pharmacology - Health - 29.05.2013
World MS Day: Novartis launches a new campaign to raise awareness of MS and the unique experiences of people living with the disease
New campaign 'MS and:Our Story' announced today, providing MS community with platform to share experiences of life with MS Launch of new Novartis social media platforms to help generate dialogue, inf

Pharmacology - Health - 23.05.2013
Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues
INTERVAL study marks first assessment of the feasibility of setting and achieving individualized goals in this difficult-to-treat population of type 2 diabetes patients Study shows elderly type 2 diabetes patients three times more likely to reach an individualized HbA1c goal with no tolerability issues with vildagliptin than placebo Previous studies raised questions of uniform HbA1c targets for elderly type 2 diabetes patients, but no trials of

Pharmacology - Health - 21.05.2013
New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations
BLAZE study showed once-daily QVA149 significantly improved patient self-reported shortness of breath and lung function compared to placebo and tiotropium 18 mc g SPARK results showed that QVA149 significantly reduced rate of all exacerbations compared to glycopyrronium 50 mcg and open-label tiotropium 18 mcg , Pooled GLOW 1 and 2 data showed once-daily Seebri Breezhaler (glycopyrronium) significantly improved lung function in the first 4 hours

Health - Pharmacology - 21.05.2013
Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement
Breast cancer is the most common cancer in women worldwide, yet survey confirms many women living with advanced form of disease feel isolated , Three in four women surveyed say they actively seek out

Health - Pharmacology - 17.05.2013
Novartis drug Afinitor significantly extended time without disease progression in women with HER2 positive advanced breast cancer
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Everolimus plus trastuzumab and vinorel

Pharmacology - Health - 10.05.2013
Novartis drug Ilaris approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Ilaris (canakinumab) is the first interleukin-1 beta inhibitor for the treatment of SJIA and the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection In Pha

Health - Pharmacology - 08.05.2013
Real-world data at ARVO highlight transformational outcomes seen with Lucentis , including lower injection frequency than in original clinical trials
UK real world study shows 59% reduction of legal blindness attributable to wet AMD since introduction of Lucentis with 9.7 injections spread over 5 years New one year REPAIR data shows visual acuity improvement of 14 letters with an average of 3.6 Lucentis injections in myopic CNV patients Largest Lucentis meta-analysis, over 10,000 patients, confirms well-established safety profile reported from extensive clinical trials and real

Health - Pharmacology - 26.04.2013
CHMP recommends conditional EU approval of Erivedge
CHMP recommends conditional EU approval of Roche's Erivedge for advanced basal cell carcinoma, a rare but potentially devastating form of skin cancer Roche announced today that the European Union's C

Pharmacology - Health - 25.04.2013
Novartis signs on to support Malaria No More’s Power of One campaign to stride towards a future without malaria
Power of One donation campaign harnesses the latest web and mobile technology to rally the global public to fight malaria Novartis will donate up to three million courses of pediatric antimalarial tr

Pharmacology - Business / Economics - 24.04.2013
Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth
Sustained commitment to innovation resulted in eight key approvals in the EU and US and strong pipeline progress EMA approved Jetrea, Bexsero , a new indication for Ilaris and a line extension for Ex

Life Sciences - Pharmacology - 24.04.2013
Scientists identify important regulator for synapse stability and plasticity
Using the fruit fly as a model organism, neurobiologists from the Friedrich Miescher Institute for Biomedical Research have identified the L1-type CAM neuroglian as an important regulator for synapse growth, function and stability. They show that the interaction of neuroglian with ankyrin provides a regulatory module to locally control synaptic connectivity and function.

Health - Pharmacology - 23.04.2013
Novartis once-daily QVA149 shows superior efficacy in reducing exacerbations, improving lung function and quality of life in COPD patients
SPARK results published in Lancet Respiratory Medicine showed that dual bronchodilator QVA149 significantly reduced the rate of moderate or severe COPD exacerbations compared to glycopyrronium 50 mcg QVA149 significantly reduced the rate of all COPD exacerbations compared to open-label tiotropium 18 mcg and glycopyrronium Basel, April 23, 2013 - Results from the 64-week SPARK study published today in Lancet Respiratory Medicine showed that inves

Health - Pharmacology - 19.04.2013
Alcon announces FDA approval of Simbrinza(TM) Suspension, a new beta blocker-free, fixed-combination therapy for glaucoma patients
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Simbrinza offers a wide range of treatm

Pharmacology - Health - 26.03.2013
Novartis confirms growing Gilenya clinical and real-world experience as number of patients treated increases to over 63,000
Growing global evidence base reinforces consistent and sustained efficacy of first once-daily oral multiple sclerosis treatment Gilenya is the only approved MS treatment shown to consistently decrease brain volume loss across studies with a significant effect seen as early as six months Low rate of brain volume loss with Gilenya sustained for up to four years in Phase III studies and for up to seven years in patients after completing a Phase II

Pharmacology - Health - 21.03.2013
New analysis shows Novartis drug Gilenya significantly reduced rate of brain volume loss across three large Phase III studies
Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS Gilenya is the first oral disease modifying treatment to show consistent effect on brain volume loss, an important indicator of disease progression Analysis of FREEDOMS II, a Phase III study, confirms Gilenya consistently reduces annualized relapse rates across disease activity, g

Health - Pharmacology - 18.03.2013
Alcon announces EU approval of Jetrea , first and only eye drug to treat sight-threatening vitreomacular traction and macular hole
Jetrea represents a breakthrough for patients with vitreomacular traction (VMT), a sight-threatening progressive condition, if left untreated One-time intravitreal injection of Jetrea has shown effic

Pharmacology - Health - 15.03.2013
Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer
LDK378 is an investigational selective inhibitor of ALK , a target found in a variety of cancers including metastatic non-small cell lung cancer (NSCLC) Breakthrough Therapy designation is based on positive early data in patients with ALK+ NSCLC who have been previously treated with crizotinib First filing for LDK378 anticipated in early 2014 Basel, March 15, 2013 - Novartis announced today that its investigational compound LDK378 has received B

Pharmacology - Health - 13.03.2013
Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every stage of multiple sclerosis
New data from three Phase III studies underlines efficacy and adds to growing global experience with Gilenya in more than 50,000 patients worldwide Data from over 500 patients treated for up to four years reinforces the known, manageable safety profile of once-daily oral Gilenya Progress reported with Novartis portfolio in studies of patients with primary-progressive MS and secondary-progressive MS, forms of the condition where treatment options

Health - Pharmacology - 01.03.2013
Novartis receives EU approval for Ilaris in patients suffering acute gouty arthritis attacks who cannot gain relief from current treatments
Ilaris is the first biologic approved in the EU for symptomatic pain relief in a gouty arthritis indication, and is administered in a single, subcutaneous injection The intense inflammatory response

Health - Pharmacology - 28.02.2013
Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa
RHD has been eliminated in most developed nations, but sub-Saharan Africa studies show at least 2-3% of school-age children suffer from this often fatal disease Collaboration between Novartis physici

Pharmacology - Health - 24.02.2013
Novartis reports Phase III data showing omalizumab improved itch in patients with a chronic form of hives who failed standard therapy[1]
Study published in NEJM today and presented tomorrow met primary endpoint in moderate to severe refractory chronic idiopathic/spontaneous urticaria (CIU/CSU) Up to two-thirds (66%) of omalizumab patients had their itch and hives well controlled within 12 weeks of initiating treatment, versus 19% for placebo , CIU/CSU can be a serious, debilitating form of hives; critical unmet need among >50% of patients who don't achieve relief with approved

Pharmacology - 15.02.2013
Novartis drug Zortress is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation Approval based on positi

Pharmacology - Life Sciences - 14.02.2013
A glimpse inside the control centres of cell communication
A glimpse inside the control centres of cell communication
Media Releases Researchers detect characteristic constructional features in a family of sensors that process signals in the human body and control physiological processes. The cells within the human body continually communicate with one another in order to fulfil their various tasks. For that purpose, they are equipped with sensors with which they receive signals from their environment.

Health - Pharmacology - 23.01.2013
Novartis drug Exjade first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia
Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate Patients with NTDT accumulate excess iron increasing their risk of complications, including liver fibrosis, cirrhosis, blood clots, and bone and vascular disease At least three quarters of a million people worldwide have NTDT - and many patients are undiagnosed until serious symptoms arise

Health - Pharmacology - 22.01.2013
Novartis receives EU approval for Bexsero , first vaccine to prevent the leading cause of life-threatening meningitis across Europe
Bexsero is indicated to help protect all age groups against meningococcal serogroup B (MenB) disease, including infants who are the most vulnerable MenB disease is associated with a high human toll f

Health - Pharmacology - 18.01.2013
Novartis receives positive CHMP opinion for Ilaris to treat patients whose acute gouty arthritis cannot be managed with standard of care
CHMP endorsed the use of Ilaris in patients with acute gouty arthritis, who suffer frequent attacks and for whom current treatments are unsuitable or ineffective Ilaris, the only approved fully human

Health - Pharmacology - 18.01.2013
Jetrea(TM) receives positive CHMP opinion, would become the first drug to treat sight-threatening vitreomacular traction and macular hole
Pivotal data showed Jetrea significantly resolved vitreomacular traction (VMT) and macular hole compared to placebo at day 28 (p<0.001) Current standard of care for VMT is surgery or "watch

Health - Pharmacology - 17.01.2013
Novartis makes progress in the fight to eliminate leprosy worldwide
Novartis advances goals set as part of a coordinated, international effort to eliminate or control 10 neglected tropical diseases (NTDs) Over 500 facilities in Tanzania now use SMS for Life to track

Health - Pharmacology - 14.01.2013
Pivotal study in The Lancet shows potential of Novartis vaccine Bexsero to help provide broad protection to infants against MenB
Phase III results show that Bexsero induced a robust immune response when administered concomitantly with routine vaccines, and also as a booster dose Data confirm Bexsero's acceptable safety and tolerability profile in infants, who are among the most vulnerable to MenB, a leading cause of meningitis Bexsero was recommended for European licensure in November 2012; upon approval, Bexsero will be the first and only broad coverage vaccine against M

Health - Pharmacology - 11.01.2013
Phase III data in The Lancet show significant benefit of Novartis drug Afinitor in patients with non-cancerous tumors associated with TSC
More than 40% of TSC patients on everolimus had their kidney tumor volume reduced by at least half with no tumor progression Separate data show 35% of TSC patients treated with everolimus had their SEGA brain tumor volume reduced by one half or more Tuberous sclerosis complex (TSC), a genetic disorder, may cause non-cancerous tumors to form in vital organs, including the kidney and brain Basel, January 10, 2013 - Data published today in The Lanc

Pharmacology - Life Sciences - 03.01.2013
How stabilised cell fibres prevent cancer cell division
How stabilised cell fibres prevent cancer cell division
Media Releases Human Health Biology Research Using Synchrotron Light Detailed structural information provides the foundation for new drugs Anti-cancer drugs used under the heading of "Chemotherapy” prevent cells from dividing. As the cells in a growing tumour divide more frequently than others, tumour cells in particular are highly damaged by chemotherapeutic drugs.

Health - Pharmacology - 21.12.2012
Novartis drug Exjade approved by European Commission
Novartis drug Exjade approved by European Commission for iron overload in patients with non-transfusion-dependent thalassemia Exjade is the first oral treatment approved in the EU for chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate At least thr

Health - Pharmacology - 15.12.2012
Novartis drug Signifor gains FDA approval as the first medication to treat Cushing’s disease, a serious endocrine disorder
As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease In the Phase III trial, most patients experienced

Health - Pharmacology - 11.12.2012
Combination therapy for incurable metastatic breast cancer to circumvent therapy resistance
Scientists discovered how resistance mechanisms arise during the treatment of incurable metastatic breast cancer and suggest strategies to circumvent these by a combination therapy. Triple-negative breast cancers are the bad guys among the different types of breast cancer. They affect younger women, metastasize more easily, are tougher to treat and once treated become therapy resistant faster.

Pharmacology - Health - 11.12.2012
Two-year data show new Novartis drug Jakavi significantly reduced myelofibrosis disease burden and suggest overall survival advantage
Jakavi demonstrated rapid reductions in spleen size and improved quality of life in Phase III studies, with results sustained over two years COMFORT-II follow-up results show Jakavi may improve overall survival vs.

Pharmacology - Health - 10.12.2012
Novartis long-term Phase III data show Ph+ CML patients on Tasigna achieved significantly deeper molecular response versus Glivec
Both newly diagnosed patients and those switching to Tasigna after long-term treatment with Glivec achieved deeper molecular response with Tasigna Data suggest correlation between early molecular res

Health - Pharmacology - 04.12.2012
Roche and the US President’s Emergency Plan for AIDS Relief (PEPFAR) partner to strengthen laboratories medicine training and knowledge on the African continent
Roche and the US President's Emergency Plan for AIDS Relief (PEPFAR) partner to strengthen laboratories medicine training and knowledge on the African continent Today Roche Diagnostics and the US Pre

Health - Pharmacology - 28.11.2012
Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
Long-term follow-up data from Jakavi Phase III trials in patients with the debilitating blood cancer, myelofibrosis Updated Phase III data in patients with Ph+ CML who switched to Tasigna after long

Health - Pharmacology - 20.11.2012
Novartis receives FDA approval for Flucelvax , the first cell-culture vaccine in US to help protect against seasonal influenza
Cell-culture technology, an alternative to traditional egg-based production, is the most significant advancement in influenza vaccine manufacturing in more than 40 years Flucelvax is the only influen

Health - Pharmacology - 16.11.2012
Novartis receives positive CHMP opinion for Bexsero
Meningococcal serogroup B (MenB) disease is easily misdiagnosed, can kill within 24 hours and may cause serious, life-long disabilities , Upon approval, Bexsero will be the first and only broad cover

This site uses cookies and analysis tools to improve the usability of the site. More information. |